HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

4th Edition of

Chemistry World Conference

June 17-19, 2024 | Paris, France

Chemistry 2024

Yong Xiao Wang

Speaker at Chemistry World Conference 2024 - Yong Xiao Wang
Albany Medical College, United States
Title : Novel therapeutics for common and devastating chronic obstructive pulmonary disease


As the third leading cause of mortality in the world, chronic obstructive pulmonary disease (COPD) is a common and devastating lung disease. However, the current clinical therapeutic options for COPD are limited, and its molecular mechanisms remain largely unknown. COPD is well characterized by airway hyperresponsiveness and remodeling, thereby leading to airflow limitation. We and other well-known scientist have unveiled that a very important player (VIP) in airway hyperresponsiveness and remodeling of COPD is an increase in intracellular calcium ([Ca2+]i) in airway smooth muscle cells (AMCs). Consistent with this view, bronchodilators including muscarinic receptor antagonists, β-adrenergic receptor agonists and corticosteroids are used as the first-line drugs in the clinical treatment of COPD, and the functional role of all these forefront drugs are associated with their inhibition of the increased [Ca2+]i in ASMCs. Recent studies from our group and others suggest that multiple ion channels, particularly inositol trisphosphate receptor (IP3R)/Ca2+ release channel, ryanodine receptor (RyR)/Ca2+ release channel and canonical transient receptor potential-3 (TRPC3) channel, play a major role in initiation and maintenance of [Ca2+]i in ASMCs and thus are essential for airway hyperresponsiveness and remodeling in COPD and/or other pulmonary diseases. Equally interestingly, IP3R, RyR and TRPC3 channels are highly sensitive to reactive oxygen species (ROS), and ROS are well known to mediate airway hyperresponsiveness and/or remodeling in COPD. We have further reveal that ROS are primarily produced by mitochondria and NADPH oxidase (NOX), but mitochondria are the primary site. Several antioxidants targeted at mitochondria and/or NOX are currently used in clinical trials and show potential effectiveness in the treatment of COPD. ROS may implement their roles in COPD by causing oxidation of IP3R, RyR and TRPC3 channels, leading to their hyperfunctions. We and other eminent investigators have further provided new evidence that virus-mediated shRNA-based genetic (specific) inhibition and highly selective pharmacological inhibitor of these channels may become more effective therapies for COPD.

Audience Take-Away:

  • My current presentation will greatly help the audience to create their future research directions
  • The finding presented may significantly assist the audience to develop novel preventive and therapeutic strategies for COPD and other relevant pulmonary diseases
  • Our research could also be used by other investigators to expand their research and/or teaching
  • All my presentation may also greatly improve experimental design, implementation, data analysis, explanations, statements, and/or conclusions


Dr. Wang has been a Full Professor in at Albany Medical College since 2006. He had his MD at Wannan Medical University in 1983, PhD at Fourth Military Medical University in 1990, postdoctoral training at Technology University of Munich in 1993 and University of Pennsylvania in 1995, and Assistant Professor (research) at University of Pennsylvania in 1997. He has had numerous publications in Nature Commun (impact factor: 17.694), Antioxid Redox Signal (8.401), Proc Natl Acad Sci USA (12.779), Nature (69.504), Circ Res (23.218), and other highly peer-reviewed journals and served as the editorial board member, section editor, and the executive committee member and/or subcommittee chair.